Clinical Trial

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-21
notable Trial sites expanded: 51 -> 60 locations 2026-07-21
Trial Details
NCT Number NCT06843239
Lead Sponsor Zura Bio Inc
Conditions Systemic Sclerosis (SSc), Scleroderma
Enrollment 80 participants
Start Date 2025-02-06
Primary Completion 2027-05 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-20